中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2010年
7期
679-682
,共4页
陆建红%陈国军%董长林%竺顺斌%陈琪%袁梅%金益军
陸建紅%陳國軍%董長林%竺順斌%陳琪%袁梅%金益軍
륙건홍%진국군%동장림%축순빈%진기%원매%금익군
Ⅰ型胶原吡啶交联终肽%肿瘤%骨转移%诊断效能%疗效观察%预后评估
Ⅰ型膠原吡啶交聯終肽%腫瘤%骨轉移%診斷效能%療效觀察%預後評估
Ⅰ형효원필정교련종태%종류%골전이%진단효능%료효관찰%예후평고
ICTP%Tumor%Bone metastasis%Diagnostic potency%Efficacy%Evaluation of prognosis
目的 探讨检测血清Ⅰ型胶原吡啶交联终肽(ICTP)在肿瘤骨转移的早期诊断效能、疗效观察及预后价值.方法 选取336例肿瘤患者,依据核素骨显像(ECT)、MRI、X线等检查结果,结合临床分为骨转移组(180例)和未转移组(156例),并对其中60例骨转移者(治疗组)治疗前后的ICTP比较分析;另选60名健康体检者为健康对照组,应用酶免疫技术(EUSA)测定各组血清ICTP水平.将未转移组中61例血清ICTP高于正常值的患者行正电子发射断层成像或X线计算机断层成像(PET/CT)检查,未发现骨转移者,每半年1次进行ECT随访并同时检测ICTP,为期2年.结果 ①骨转移组血清ICTP[(10.47±7.56)μg/L]显著高于未转移组[(5.12±2.33)μg/L](t=9.503,P=0.000)和健康对照组[(2.76±0.62)μg/L](t=13.691,P=0.000).②未转移组中61例血清ICTP高于正常值者,ICTP为(5.98±1.95)μg/L,经PET/CT检查发现骨转移22例,余39例经2年随访发生骨转移26例,ICTP由(5.92±1.61)μg/L上升至(8.73±3.11)μg/L(t=4.612,P=0.000).③治疗有效者血清ICTP较治疗前下降,从(13.22±4.65)μg/L降至(7.18±3.54)μg/L(t=10.076,P=0.000),且疗效越显著,下降越明显.结论 血清ICTP能用于肿瘤骨转移的早期辅诊、筛查和疗效观察,并可监测骨转移的发生及预后判断.
目的 探討檢測血清Ⅰ型膠原吡啶交聯終肽(ICTP)在腫瘤骨轉移的早期診斷效能、療效觀察及預後價值.方法 選取336例腫瘤患者,依據覈素骨顯像(ECT)、MRI、X線等檢查結果,結閤臨床分為骨轉移組(180例)和未轉移組(156例),併對其中60例骨轉移者(治療組)治療前後的ICTP比較分析;另選60名健康體檢者為健康對照組,應用酶免疫技術(EUSA)測定各組血清ICTP水平.將未轉移組中61例血清ICTP高于正常值的患者行正電子髮射斷層成像或X線計算機斷層成像(PET/CT)檢查,未髮現骨轉移者,每半年1次進行ECT隨訪併同時檢測ICTP,為期2年.結果 ①骨轉移組血清ICTP[(10.47±7.56)μg/L]顯著高于未轉移組[(5.12±2.33)μg/L](t=9.503,P=0.000)和健康對照組[(2.76±0.62)μg/L](t=13.691,P=0.000).②未轉移組中61例血清ICTP高于正常值者,ICTP為(5.98±1.95)μg/L,經PET/CT檢查髮現骨轉移22例,餘39例經2年隨訪髮生骨轉移26例,ICTP由(5.92±1.61)μg/L上升至(8.73±3.11)μg/L(t=4.612,P=0.000).③治療有效者血清ICTP較治療前下降,從(13.22±4.65)μg/L降至(7.18±3.54)μg/L(t=10.076,P=0.000),且療效越顯著,下降越明顯.結論 血清ICTP能用于腫瘤骨轉移的早期輔診、篩查和療效觀察,併可鑑測骨轉移的髮生及預後判斷.
목적 탐토검측혈청Ⅰ형효원필정교련종태(ICTP)재종류골전이적조기진단효능、료효관찰급예후개치.방법 선취336례종류환자,의거핵소골현상(ECT)、MRI、X선등검사결과,결합림상분위골전이조(180례)화미전이조(156례),병대기중60례골전이자(치료조)치료전후적ICTP비교분석;령선60명건강체검자위건강대조조,응용매면역기술(EUSA)측정각조혈청ICTP수평.장미전이조중61례혈청ICTP고우정상치적환자행정전자발사단층성상혹X선계산궤단층성상(PET/CT)검사,미발현골전이자,매반년1차진행ECT수방병동시검측ICTP,위기2년.결과 ①골전이조혈청ICTP[(10.47±7.56)μg/L]현저고우미전이조[(5.12±2.33)μg/L](t=9.503,P=0.000)화건강대조조[(2.76±0.62)μg/L](t=13.691,P=0.000).②미전이조중61례혈청ICTP고우정상치자,ICTP위(5.98±1.95)μg/L,경PET/CT검사발현골전이22례,여39례경2년수방발생골전이26례,ICTP유(5.92±1.61)μg/L상승지(8.73±3.11)μg/L(t=4.612,P=0.000).③치료유효자혈청ICTP교치료전하강,종(13.22±4.65)μg/L강지(7.18±3.54)μg/L(t=10.076,P=0.000),차료효월현저,하강월명현.결론 혈청ICTP능용우종류골전이적조기보진、사사화료효관찰,병가감측골전이적발생급예후판단.
Objective To evaluate the serum pyridinoline cross-linked carboxyteminal telopeptide of type Ⅰ collagen ( ICTP) in the early diagnosis potency,efficacy and prognosis of tumor bone metastasis. Methods According to emission computed tomography(ECT) ,MRI and X-ray results,336 cases of tumor were divided into higher ICTP (5. 98 ± 1. 95μg/L ) than normal values. Twenty-two cases were identified bone metastasis through PET/CT examination. 26 cases were identified bone the effective cases decreased from( 13. 22 ± 4.65)μg/L (before treatment) to (7. 18 ±3. 54)μg/L (after treatment) (t = 10. 076,P = 0. 000). Conclusions Serum ICTP is helpful for the early diagnosis, screening and efficacy evaluation of tumor bone metastasis. It could be used for monitoring the occurrence of tumor bone metastasis and its prognosis.
